Prevalence of PIMDINAC criteria and recommendations for therapeutic appropriateness in multiple sclerosis patients

Abstract

Purpose The ageing population with multiple sclerosis could be related to potentially inappropriate medication prescriptions, drug-drug interactions and therapeutic non-adherence. The PIMDINAC criteria aim to jointly analyse these problems. The aim of the study is to determine the prevalence of PIMDINAC criteria in a multiple sclerosis population aged 55 years or older. Methods Observational, cross-sectional study that included patients over 55 years of age in pharmacotherapy follow-up between November 2022 and January 2023. The main variable was the percentage of compliance with the PIMDINAC criteria. Results 95 patients were included, detecting the presence of PIMDINAC criteria in 67.4%. The most frequently detected was non-adherence to concomitant treatment in 84.4% of cases followed by drug-drug interactions in 56.2% and potentially inappropriate medication in 25%. The number of drugs and polypharmacy were related to a higher occurrence of PIMDINAC criteria. A total of 20 pharmaceutical interventions were performed in 17 patients (17.9%), PIM criteria were responsible for 11 interventions, NAC for 7 and DI for 2. Of the 11 interventions on PIM criteria, 9 (81.8%) were accepted resulting in the discontinuation of 15 drugs that were appropriately prescribed. Conclusion The prevalence of PIMDINAC criteria in elderly MS patients is high.